Quotient Sciences
Ruddington, Nottingham, NG11 6JS, United Kingdom
NCT Number: NCT03878264
This study will evaluate the absolute bioavailability of CORT118335 and determine the mass balance recovery, absorption, metabolism and elimination, and metabolite profile and identification of metabolite structures following a single oral dose of CORT118335 in healthy male participants.
Looking for future studies?
Notify Me18 year–65 year
Male
Interventional
Phase 1
Ruddington, Nottingham, NG11 6JS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
Other names: Treatment A
14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
Other names: Treatment B
14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
Other names: Treatment C
Time frame: Predose and at pre-specified time points up to Day 12
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 12 after dosing
Time frame: Pre-dose and at pre-specified time points up to Day 15 after dosing
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Time frame: Until the mass balance criteria have been met by all participants (estimated Day 17)
Corcept Therapeutics
Industry
An Open-label, 2-part Study Designed to Assess the Absolute Bioavailability of CORT118335 and Determine the Mass Balance Recovery, Absorption, Metabolism and Elimination, and Metabolite Profile and Identification of Metabolite Structures of [14C]-CORT118335 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details